Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Mostrar otras versiones (1)

BACKGROUND/AIMS: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. METHODS: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jae-Woo, Park, Hae-Sim, Park, Choon-Sik, Cho, Sang-Heon, Choi, Inseon S., Moon, Hee-Bom, Kwon, Soon Seog, Yoon, Ho Joo, Park, Jung Won, Lee, Jong-Myung, Choi, Dong-Chull, Choi, Byoung Whui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273830/
https://www.ncbi.nlm.nih.gov/pubmed/34237826
http://dx.doi.org/10.3904/kjim.2020.549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273830/
https://www.ncbi.nlm.nih.gov/pubmed/34237826
http://dx.doi.org/10.3904/kjim.2020.549

Ejemplares similares